Journal Mobile Options
Table of Contents
Vol. 23, No. 2, 2002
Issue release date: March–April 2002 (June 2002)
Tumor Biol 2002;23:93–102
(DOI:10.1159/000059711)

Egr1 Transcription Factor: Multiple Roles in Prostate Tumor Cell Growth and Survival

Adamson E.D. · Mercola D.
aBurnham Institute, La Jolla, Calif., and bSidney Kimmel Cancer Center, San Diego, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The transcription factor, Egr1, so-called because it is encoded by the immediate early growth response gene, Egr1, is rapidly induced by growth factors to transduce the proliferative signal. The induction of Egr1 by external stimuli is generally transient but appears to be sustained in some prostate tumor cell lines and tumors, suggesting that Egr1 stimulates tumor cell growth. In contradiction, in breast, lung and brain tumors, Egr1 expression is often absent or reduced and when re-expressed, results in growth suppression. Re-expression of Egr1 in tumor cells also leads to antiapoptotic activity, which would encourage tumor cell survival. Egr1 is also required for, or stimulates, the differentiation of several cell types. Another contradiction is that after stress stimuli to some cell types, Egr1 is required for programmed cell death or apoptosis in both normal and tumor cells. Egr1 also plays a role in tumor progression, through the hypoxic signal generated in growing tumors. Egr1 is highly induced under these conditions and its activities stimulate angiogenesis and improved survival of tumor cells. How this large agenda can be achieved lies in the choice of Egr1 target genes, and varying patterns of coordinated expression have been described, but the mechanisms for this choice are not clear. This review points to areas where research should be focussed.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Sukhatme VP, Cao X, Chang LC, Tsai-Morris C-H, Stamenkovitch D, Ferreira PCP, Cohen DR, Edwards SA, Shows TB, Curran T, Le Beau MM, Adamson ED: A zinc finger-encoding gene coregulated with c-fos during growth and differentiation and after cellular depolarization. Cell 1988;53:37–43.

    External Resources

  2. Milbrandt J: Nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 1987;238:797–799.
  3. Christy B, Lau LF, Nathans D: A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with ‘zinc finger’ sequence. Proc Natl Acad Sci USA 1988;85:7857–7861.
  4. Chavrier P, LeMaire P, Revelant X, Bravo R, Charney P: Characterization of a mouse multiple family that encodes zinc finger structures. Mol Cell Biol 1988;8:1319–1326.
  5. Lim RW, Varnum BC, Herschman HR: Cloning of tetradecanoyl phorbol ester-induced ‘primary response’ sequences and their expression in density-arrested Swiss 3T3 cells and a TPA non-proliferative variant. Oncogene 1987;1:263–270.
  6. Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM, Mercola D, Adamson ED: Decreased Egr-1 expression In human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 1997;72:102–109.
  7. Levin WJ, Press MF, Gaynor RB, Sukhatme VP, Boone TC, Reissmann PT, Figlin RA, Holmes EC, Souza LM, Slamon DJ: Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group. Oncogene 1995;11:1261–1269.

    External Resources

  8. Calogero A, Arcella A, De Gregorio G, Porcellini A, Mercola D, Liu C, Lombari V, Zani M, Giannini G, Gagliardi FM, Caruso R, Gulino A, Frati L, Ragona G: The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res 2001;7:2788–2796.

    External Resources

  9. Blok LJ, Grossmann ME, Perry JE, Tindall DJ: Characterization of an early growth response gene, which encodes a zinc finger transcription factor, potentially involved in cell cycle regulation. Mol Endocrinol 1995;9:1610–1620.

    External Resources

  10. Fautsch MP, Vrabel A, Subramaniam M, Hefferen TE, Spelsberg TC, Wieben ED: TGFbeta-inducible early gene (TIEG) also codes for early growth response alpha (EGRalpha): Evidence of multiple transcripts from alternate promoters. Genomics 1998;51:408–416.
  11. Kawai-Kowase K, Kurabayashi M, Hoshino Y, Ohyama Y, Nagai R: Transcriptional activation of the zinc finger transcription factor BTEB2 gene by Egr-1 through mitogen-activated protein kinase pathways in vascular smooth muscle cells. Circ Res 1999;85:787–795.
  12. Svaren J, Sevetson BR, Apel ED, Zimonjic DB, Popescu NC, Milbrandt J: NAB2, a corepressor of NGFI-A (Egr-1) and Krox20, is induced by proliferative and differentiative stimuli. Mol Cell Biol 1996;16:3545–3553.
  13. Swirnoff AH, Apel ED, Svaren J, Sevetson BR, Zimonjic DB, Popescu NC, Milbrandt J: Nab1, a corepressor of Ngfi-a (Egr-1), contains an active transcriptional repression domain. Mol Cell Biol 1998;18:512–524.

    External Resources

  14. Ehrengruber MU, Muhlebach SG, Sohrman S, Leutenegger CM, Lester HA, Davidson N: Modulation of early growth response (EGR) transcription factor-dependent gene expression by using recombinant adenovirus. Gene 2000;258:63–69.
  15. Qu Z, Wolfraim L, Svaren J, Ehrengruber MU, Davidson N, Milbrandt J: The transcriptional corepressor NAB2 inhibits NGF-induced differentiation of PC12 cells. J Cell Biol 1998;142:1075–1082.
  16. Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J: EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 2001;30:355–368.

    External Resources

  17. Sukhatme VP: Early transcriptional events in cell growth: the Egr family. J Am Soc Nephrol 1990;1:859–866.
  18. Chien S, Li S, Shyy YJ: Effects of mechanical forces on signal transduction and gene expression in endothelial cells. Hypertension 1998;31:162–169.
  19. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G: Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann NY Acad Sci 2000;902:230–239; discussion 239–240.
  20. Mackman N: Regulation of the tissue factor gene. Thromb Haemost 1997;78:747–754.
  21. Khachigian LM, Collins T: Early growth response factor 1: A pleiotropic mediator of inducible gene expression. J Mol Med 1998;76:613–616.

    External Resources

  22. Rauscher FJ 3rd: Tumor suppressor genes which encode transcriptional repressors: Studies on the EGR and Wilms’ tumor (WT1) gene products. Adv Exp Med Biol 1993;348:23–29.
  23. Gashler A, Sukhatme VP: Early growth response protein 1 (Egr-1): Prototype of a zinc-finger family of transcription factors. Prog Nucleic Acid Res Mol Biol 1995;50:191–224.
  24. Yan SF, Pinsky DJ, Mackman N, Stern DM: Egr-1: Is it always immediate and early? J Clin Invest 2000;105:553–554.
  25. Russo MW, Sevetson BR, Milbrandt J: Identification of NAB1, a repressor of NGFI-A- and Krox20-mediated transcription. Proc Natl Acad Sci USA 1995;92:6873–6877.

    External Resources

  26. Houston P, Campbell CJ, Svaren J, Milbrandt J, Braddock M: The transcriptional corepressor NAB2 blocks Egr-1-mediated growth factor activation and angiogenesis. Biochem Biophys Res Commun 2001;283:480–486.

    External Resources

  27. Jin DK, Kang SJ, Kim SJ, Bang EH, Hwang HZ, Tadokoro K, Yamada M, Kohsaka T: Transcriptional regulation of PDGF-A and TGF-beta by +KTS WT1 deletion mutants and a mutant mimicking Denys-Drash syndrome. Ren Fail 1999;21:685–694.
  28. Scharnhorst V, Menke AL, Attema J, Haneveld JK, Riteco N, van Steenbrugge GJ, van der Eb AJ, Jochemsen AG: EGR-1 enhances tumor growth and modulates the effect of the Wilms’ tumor 1 gene products on tumorigenicity. Oncogene 2000;19:791–800.

    External Resources

  29. Cui MZ, Parry GCN, Oeth P, Larson H, Smith M, Huang RP, Adamson ED, Mackman N: Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1. J Biol Chem 1996;271:2731–2739.
  30. Fukada T, Tonks NK: The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase. J Biol Chem 2001;276:25512–25519.
  31. Silverman ES, Collins T: Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 1999;154:665–670.
  32. Lee SL, Tourtellotte LC, Wesselschmidt RL, Milbrandt J: Growth and differentiation proceeds normally in cells deficient in the immediate early gene NGFI-A. J Biol Chem 1995;270:9971–9977.
  33. Lee SL, Sadovsky Y, Swirnoff AH, Polish JA, Goda P, Gavrilina G, Milbrandt J: Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science 1996;273:1219–1221.
  34. Topilko P, Schneidermaunoury S, Levi G, Trembleau A, Gourdji D, Driancourt MA, Rao CV, Charnay P: Multiple pituitary and ovarian defects in Krox-24 (Ngfi-a, Egr-1)-targeted mice. Mol Endocrinol 1998;12:107–122.
  35. Tourtellotte WG, Nagarajan R, Bartke A, Milbrandt J: Functional compensation by Egr4 in Egr1-dependent luteinizing hormone regulation and Leydig cell steroidogenesis. Mol Cell Biol 2000;20:5261–5268.
  36. Yan SF, Zou YS, Gao Y, Zhai C, Mackman N, Lee SL, Milbrandt J, Pinsky D, Kisiel W, Stern D: Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci USA 1998;95:8298–8303.
  37. Yan SF, Fujita T, Lu JS, Okada K, Zou YS, Mackman N, Pinsky DJ, Stern DM: Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 2000;6:1355–1361.
  38. Saadane N, Alpert L, Chalifour LE: Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice. Am J Physiol 2000;278:H796–H805.
  39. Saadane N, Yue P, Alpert L, Mitmaker B, Kirby GM, Chalifour LE: Diminished molecular response to doxorubicin and loss of cardioprotective effect of dexrazoxane in Egr-1 deficient female mice. Can J Physiol Pharmacol 2001;79:533–544.

    External Resources

  40. Zaiou M, Azrolan N, Hayek T, Wang H, Wu L, Haghpassand M, Cizman B, Madaio MP, Milbrandt J, Marsh JB, Breslow JL, Fisher EA: The full induction of human apoprotein A-I gene expression by the experimental nephrotic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor 1. J Clin Invest 1998;101:1699–1707.
  41. Foster BA, Kaplan PJ, Greenberg NM: Peptide growth factors and prostate cancer: New models, new opportunities (review). Cancer Metastasis Rev 1998;17:317–324.

    External Resources

  42. Hsu CX, Ross BD, Chrisp CE, Derrow SZ, Charles LG, Pienta KJ, Greenberg NM, Zeng Z, Sanda MG: Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol 1998;160:1500–1505.
  43. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM: The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59:2203–2209.
  44. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MK, Milbrandt J: EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 2000;275:38524–38531.
  45. Thigpen AE, Cala KM, Guileyardo JM, Molberg KH, McConnell JD, Russell DW: Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. J Urol 1996;155:975–981.
  46. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ: Expression of early growth response genes in human prostate cancer. Cancer Res 1998;58:2461–2468.
  47. Garabedian EM, Humphrey PA, Gordon JI: A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci USA 1998;95:15382–15387.
  48. Abdulkadir SA, Qu ZC, Garabedian E, Song SK, Peters TJ, Svaren J, Carbone JM, Naughton CK, Catalona WJ, Ackerman JJH, Gordon JI, Humphrey PA, Milbrandt J: Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 2001;7:101–107.
  49. Bae SK, Bae MH, Ahn MY, Son MJ, Lee YM, Bae MK, Lee OH, Park BC, Kim KW: Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Canc Res 1999;59:5989–5994.
  50. Lee YI, Kim SJ: Transcriptional repression of human insulin-like growth factor-II P4 promoter by Wilms’ tumor suppressor WT1. DNA Cell Biol 1996;15:99–104.

    External Resources

  51. Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJI: Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992;257:674–678.
  52. Damon SE, Plymate SR, Carroll JM, Sprenger CC, Dechsukhum C, Ware JL, Roberts CT Jr: Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 2001;142:21–27.
  53. Ravindranath N, Wion D, Brachet P, Djakiew D: Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001;22:432–443.

    External Resources

  54. Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR, Haber DA: WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995;14:4662–4675.
  55. Liu X-W, Gong L-J, Guo L-Y, Katagiri Y, Jiang H, Wang Z-Y, Johnson AC, Guroff G: The Wilms’ tumor gene product WT1 mediates the down-regulation of the rat epidermal growth factor receptor by nerve growth factor in PC12 cells. J Biol Chem 2001;276:5068–5073.
  56. Nishi H, Nishi KH, Johnson AC: Early growth response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 2002;62:827–834.

    External Resources

  57. Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA: The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 1999;98:663–673.
  58. Niemeyer CC, Spencer-Dene B, Wu J-X, Adamson ED: Preneoplastic mammary tumor markers: Cripto and amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice. Int J Cancer 1999;81:588–591.
  59. Seth D, Shaw K, Jazayeri J, Leedman PJ: Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer 1999;80:657–669.
  60. von Bossanyi P, Sallaba J, Dietzmann K, Warich-Kirches M, Kirches E: Correlation of TGF-alpha and EGF-receptor expression with proliferative activity in human astrocytic gliomas. Pathol Res Pract 1998;194:141–147.
  61. Torring N, Jorgensen PE, Sorensen BS, Nexo E: Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000;20:91–95.

    External Resources

  62. Delbridge GJ, Khachigian LM: FGF-1-induced platelet-derived growth factor-A chain gene expression in endothelial cells involves transcriptional activation by early growth response factor-1. Circ Res 1997;81:282–288.
  63. Silverman ES, Khachigian LM, Lindner V, Williams AJ, Collins T: Inducible PDGF A-chain transcription in smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3. Am J Physiol 1997;273:H1415–H1426.

    External Resources

  64. Sumpio BE, Du W, Galagher G, Wang X-J, Khachigian LM, Collins T, Gimbrone MA Jr, Resnick N: Regulation of PDGF-B in endothelial cells exposed to cyclic strain. Arterioscler Thromb Vasc Biol 1998;18:349–355.
  65. Wang D, Mayo MW, Baldwin AS: Basic fibroblast growth factor transcriptional autoregulation requires EGR-1. Oncogene 1997;14:2291–2299.

    External Resources

  66. Biesiada E, Razandi M, Levin ER: Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. J Biol Chem 1996;271:18576–18581.
  67. Russell PJ, Bennett S, Stricker P: Growth factor involvement in progression of prostate cancer (review). Clin Chem 1998;44:705–723.
  68. Sciavolino PJ, Abate-Shen C: Molecular biology of prostate development and prostate cancer (review). Ann Med 1998;30:357–368.

    External Resources

  69. Fudge K, Wang CY, Stearns ME: Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 1994;7:549–554.
  70. Kim HE, Han SJ, Kasza T, Han R, Choi HS, Palmer KC, Kim HR: Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function. Int J Radiat Oncol Biol Phys 1997;39:731–736.
  71. Yan YX, Nakagawa H, Lee MH, Rustgi AK: Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter. J Biol Chem 1997;272:33181–33190.
  72. Molnar G, Crozat A, Pardee AB: The immediate-early gene Egr-1 regulates the activity of the thymidine kinase promoter at the G0-to-G1 transition of the cell cycle. Mol Cell Biol 1994;14:5242–5248.

    External Resources

  73. Muller C, Yang R, Beck-von-Peccoz L, Idos G, Verbeek W, Koeffler HP: Cloning of the cyclin A1 genomic structure and characterization of the promoter region. GC boxes are essential for cell cycle-regulated transcription of the cyclin A1 gene. J Biol Chem 1999;274:11220–11228.
  74. Li RS, Law GL, Seifert RA, Romaniuk PJ, Morris DR: Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1. Exp Cell Res 1999;247:257–266.
  75. Liu X, Wang L, Lin Y, Teng Q, Zhao C, Hu H, Chi W: Ornithine decarboxylase activity and its gene expression are increased in benign hyperplastic prostate. Prostate 2000;43:83–87.
  76. Khachigian LM, Collins T: Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium. Circ Res 1997;81:457–461.
  77. Kroon ME, Koolwijk P, van der Vecht B, van Hinsbergh VW: Hypoxia in combination with FGF-2 induces tube formation by human microvascular endothelial cells in a fibrin matrix: Involvement of at least two signal transduction pathways. J Cell Sci 2001;114:825–833.

    External Resources

  78. Stubbs AP, Abel PD, Golding M, Bhangal G, Wang Q, Waxman J, Stamp GW, Lalani EN: Differentially expressed genes in hormone refractory prostate cancer: Association with chromosomal regions involved with genetic aberrations. Am J Pathol 1999;154:1335–1343.
  79. Liu CT, Yao J, Mercola D, Adamson E: The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 2000;275:20315–20323.
  80. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HFJ, Hampton GM: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974–5978.

    External Resources

  81. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Warson MA, Milbrandt J: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61:5692–5696.

    External Resources

  82. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822–826.
  83. Grimaldi P, Geremia R, Albanesi C, Rossi P: The same sequence mediates activation of the human urokinase promoter by cAMP in mouse Sertoli cells and by SV40 large T antigen in COS cells. Mol Cell Endocrinol 1996;117:167–173.

    External Resources

  84. Shovlin CL, Scott J: Inherited diseases of the vasculature. Annu Rev Physiol 1996;58:483–507.
  85. Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ, Milbrandt J: Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000;31:443–447.
  86. Chen J, Bierhaus A, Schiekofer S, Andrassy M, Chen B, Stern DM, Nawroth PP: Tissue factor – a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001;86:334–345.

    External Resources

  87. de Belle I, Mercola D, Adamson ED: Method for cloning in vivo targets of the Egr-1 transcription factor. Biotechniques 2000;29:162–169.

    External Resources

  88. Haber DA, Englert C, Maheswaran S: Functional properties of WT1. Med Pediatr Oncol 1996;27:453–455.
  89. Lehmann U, Brocke P, Dittmer J, Nordheim A: Characterization of the human elk-1 promoter. Potential role of a downstream intronic sequence for elk-1 gene expression in monocytes. J Biol Chem 1999;274:1736–1744.
  90. Kinane TB, Finder JD, Kawashima A, Brown D, Abbate M, Shang C, Fredericks WJ, Rauscher F Jr, Sukhatme VP, Ercolani L: Growth of LLC-PK1 renal cells is mediated by EGR1 up-regulation of G protein alpha i-2 protooncogene transcription. J Biol Chem 1994;269:27503–27509.

    External Resources

  91. Kinane TB, Finder JD, Kawashima A, Brown D, Abbate M, Fredericks WJ, Sukhatme VP, Rauscher F Jr, Ercolani L: LLC-PK1 cell growth is repressed by WT1 inhibition of G-protein alpha i-2 protooncogene transcription (published erratum appears in J Biol Chem 1996 Mar 29;271(13):7874). J Biol Chem 1995;270:30760–30764.
  92. Tournay O, Benezra R: Transcription of the dominant-negative helix-loop-helix protein Id1 is regulated by a protein complex containing the immediate-early response gene Egr1. Mol Cell Biol 1996;16:2418–2430.

    External Resources

  93. Dong G, Rajah R, Vu T, Hoffman AR, Rosenfeld RG, Roberts CT Jr, Peehl DM, Cohen P: Decreased expression of Wilms’ tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J. Clin Endocrinol Metab 1997;82:2198–2203.
  94. Zhu JL, Kaytor EN, Pao CI, Meng XP, Phillips LS: Involvement of Sp1 in the transcriptional regulation of the rat insulin-like growth factor-1 gene. Mol Cell Endocrinol 2000;164:205–218.

    External Resources

  95. Lee S, Park U, Lee YI: Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites. Virology 2001;283:167–177.
  96. Werner H, Rauscher FJI, Sukhatme VP, Drummond IA, Roberts CTJ, LeRoith D: Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J Biol Chem 1994;269:12577–12582.

    External Resources

  97. Liu Z, Mittanck DW, Kim S, Rotwein P: Control of insulin-like growth factor-II/mannose 6-phosphate receptor gene transcription by proximal promoter elements. Mol Endocrinol 1995;9:1477–1487.
  98. Elminger MW, Bell M, Schuett BS, Langkamp M, Kutoh E, Ranke MB: Transactivation of the IGFBP-2 promoter in human tumor cell lines. Mol Cell Endocrinol 2001;175:211–218.
  99. Binkert C, Margot JB, Landwehr J, Heinrich G, Schwander J: Structure of the human insulin-like growth factor binding protein-2 gene. Mol Endocrinol 1992;6:826–836.
  100. Rozek D, Pfeifer GP: In vivo protein-DNA interactions at the c-jun promoter: Preformed complexes mediate the UV response. Mol Cell Biol 1993;13:5490–5499.

    External Resources

  101. Moshier JA, Skunca M, Wu W, Boppana SM, Rauscher FJ 3rd, Dosescu J: Regulation of ornithine decarboxylase gene expression by the Wilms’ tumor suppressor WT1. Nucleic Acids Res 1996;24:1149–1157.

    External Resources

  102. Wang ZY, Qiu QQ, Gurrieri M, Huang J, Deuel TF: WT1, the Wilms’ tumor suppressor gene product, represses transcription through an interactive nuclear protein. Oncogene 1995;10:1243–1247.

    External Resources

  103. Wang ZY, Madden SL, Deuel TF, Rauscher FJ 3rd: The Wilms’ tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 1992;267:21999–20002.
  104. Khachigian LM, Lindner V, Williams AJ, Collins T: Egr-1-induced endothelial gene expression: A common theme in vascular injury. Science 1996;271:1427–1431.
  105. Peng Y, Du K, Ramirez S, Diamond RH, Taub R: Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1. Egr-1 activation is an early event in liver regeneration. J Biol Chem 1999;274:4513–4520.
  106. Kilbourne EJ, Widom R, Harnish DC, Malik S, Karathanasis SK: Involvement of early growth response factor Egr-1 in apolipoprotein AI gene transcription. J Biol Chem 1995;270:7004–7010.
  107. Yang X, Pater A, Tang SC: Cloning and characterization of the human BAG-1 gene promoter: Upregulation by tumor-derived p53 mutants. Oncogene 1999;18:4546–4553.

    External Resources

  108. Naishiro Y, Adachi M, Okuda H, Yawata A, Mitaka T, Takayama S, Reed JC, Hinoda Y, Imai K: BAG-1 accelerates cell motility of human gastric cancer cells. Oncogene 1999;18:3244–5132.

    External Resources

  109. Huang RP, Fan Y, Peng A, Zeng ZL, Reed JC, Adamson ED, Boynton AL: Suppression of human fibrosarcoma cell growth by transcription factor, Egr-1, involves down-regulation of Bcl-2. Int J Cancer 1998;77:880–886.
  110. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, Weissman BE, Baldwin AS: WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999;18:3990–4003.

    External Resources

  111. Hosono S, Gross I, English MA, Hajra KM, Fearon ER, Licht JD: E-cadherin is a WT1 target gene. J Biol Chem 2000;275:10943–10953.
  112. Maltzman JS, Carman JA, Monroe JG: Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes. Mol Cell Biol 1996;16:2283–2294.
  113. Fang MA, Glackin CA, Sadhu A, McDougall S: Transcriptional regulation of alpha 2(I) collagen gene expression by fibroblast growth factor-2 in MC3T3-E1 osteoblast-like cells. J Cell Biochem 2001;80:550–559.
  114. Maltzman JS, Carmen JA, Monroe JG: Transcriptional regulation of the Icam-1 gene in antigen receptor- and phorbol ester-stimulated B lymphocytes: Role for transcription factor EGR1. J Exp Med 1996;183:1747–1759.
  115. Iwami K, Ashizawa N, Do YS, Graf K, Hsueh WA: Comparison of ANG II with other growth factors on Egr-1 and matrix gene expression in cardiac fibroblasts. Am J Physiol 1996;270:H2100–H2107.

    External Resources

  116. Cogswell PC, Mayo MW, Baldwin AS: Involvement of Egr-1/RelA synergy in distinguishing T cell activation from tumor necrosis factor-alpha-induced NF-kappa B1 transcription. J Exp Med 1997;185:491–497.
  117. Thottassery JV, Sun D, Zambetti GP, Troutman A, Sukhatme VP, Schuetz EG, Schuetz JD: Sp1 and egr-1 have opposing effects on the regulation of the rat Pgp2/mdr1b gene. J Biol Chem 1999;274:3199–3206.
  118. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM: Early growth response-1-dependent apoptosis is mediated by p53. J. Biol Chem 1997;272:20131–20138.
  119. Das A, Chendil D, Dey S, Mohiuddin M, Milbrandt J, Rangnekar VM, Ahmed MM: Ionizing radiation down-regulates p53 protein in primary Egr-1(–/–) mouse embryonic fibroblast cells causing enhanced resistance to apoptosis. J Biol Chem 2001;276:3279–3286.
  120. Michel D, Chatelain G, North S, Brun G: Stress-induced transcription of the clusterin/apoJ gene. Biochem J 1997;328:45–50.
  121. Hasan Q, Ruger BM, Tan ST, Gush J, Davis PF: Clusterin/apoJ expression during the development of hemangioma. Hum Pathol 2000;31:691–697.
  122. Laniel MA, Bergeron MJ, Poirier GG, Guerin SL: A nuclear factor other than Sp1 binds the GC-rich promoter of the gene encoding rat poly(ADP-ribose) polymerase in vitro. Biochem Cell Biol 1997;75:427–434.
  123. Kramer B, Meichle A, Hensel G, Charnay P, M K: Characterization of an Krox-24/Egr-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta 1994;1219:413–421.
  124. Yao J, Mackman N, Edgington TS, Fan ST: Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells – Regulation by Egr-1, C-Jun, and Nf-kappa-B transcription factors. J Biol Chem 1997;272:17795–17801.
  125. Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA: Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem 1999;274:22679–22685.
  126. Akuzawa N, Kurabayashi M, Ohyama Y, Arai M, Nagai R: Zinc finger transcription factor Egr-1 activates Flt-1 gene expression in THP-1 cells on induction for macrophage differentiation. Arterioscler Thromb Vasc Biol 2000;20:377–384.

    External Resources

  127. Vidal F, Aragones J, Alfranca A, de Landazuri MO: Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: Role of transcription factor Egr-1. Blood 2000;95:3387–3395.
  128. Han YP, Tuan TL, Hughes M, Wu H, Garner WL: Transforming growth factor-beta – and tumor necrosis factor-alpha -mediated induction and proteolytic activation of MMP-9 in human skin. J Biol Chem 2001;276:22341–22350.
  129. Rao VH, Singh RK, Delimont DC, Finnell RH, Bridge JA, Neff JR, Garvin BP, Pickering DL, Sanger WG, Buehler BA, Schaefer GB: Transcriptional regulation of MMP-9 expression in stromal cells of human giant cell tumor of bone by tumor necrosis factor-alpha. Int J Oncol 1999;14:291–300.
  130. Kim DR, Sharmin S, Inoue M, Kido H: Cloning and expression of novel mosaic serine proteases with and without a transmembrane domain from human lung. Biochim Biophys Acta 2001;1518:204–209.

    External Resources

  131. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 2001;13:85–94.
  132. Pawar S, Kartha S, Toback FG: Differential gene expression in migrating renal epithelial cells after wounding. J Cell Physiol 1995;165:556–565.
  133. Kroon ME, Koolwijk P, van Goor H, Weidle UH, Collen A, van der Pluijm G, van Hinsbergh VW: Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol 1999;154:1731–1742.
  134. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD: Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 1999;274:18428–18437.
  135. Silins G, Grimmond S, Egerton M: Hayward N: Analysis of the promoter region of the human VEGF-related factor gene. Biochem Biophys Res Commun 1997;230:413–418.
  136. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E: Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999;93:3811–3823.
  137. de Belle I, Huang R-P, Fan Y, Liu C, Mercola D, Adamson ED: p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. Oncogene 1999;18:3633–3642.

    External Resources

  138. Soejima H, McLay J, Hatada I, Mukai T, Jinno Y, Niikawa N, Yun K: Comparative reverse transcription-polymerase chain reaction and in situ hybridization analyses of human imprinted p57KIP2 and insulin-like growth factor 2 gene transcripts in fetal kidney and Wilms’ tumors using archival tissue. Lab Invest 1998;78:19–28.
  139. Shingu T, Bornstein P: Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene. J Biol Chem 1994;269:32551–32557.

    External Resources

  140. Liu C, Adamson E, Mercola D: Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor b1. Proc Natl Acad Sci USA 1996;93:11831–11836.
  141. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I: The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nature Cell Biol 2001;3:1124–1128.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50